Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges

The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaurasiya, Shyambabu, Fong, Yuman, Warner, Susanne G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352900/
https://www.ncbi.nlm.nih.gov/pubmed/32604787
http://dx.doi.org/10.3390/cancers12061699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352900/
https://www.ncbi.nlm.nih.gov/pubmed/32604787
http://dx.doi.org/10.3390/cancers12061699

Ejemplares similares